Ophthotech is a biopharmaceutical company focusing on the development of therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Co. is developing Zimura® (avacincaptad pegol), its complement C5 inhibitor, for dry and wet forms of age-related macular degeneration, which is a disorder of the central portion of the retina, known as the macula, that may result in loss of central vision, and autosomal recessive Stargardt disease, which is an orphan inherited retinal disease that also may result in loss of central and peripheral vision. We show 23 historical shares outstanding datapoints in our coverage of OPHT's shares outstanding history.
Understanding the changing numbers of OPHT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like OPHT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching OPHT by allowing them to research OPHT shares outstanding history
as well as any other stock in our coverage universe. |
Free OPHT Email Alerts:
Video: Shares Outstanding Importance
